Kwang-hyub C. Han
Experienced in Transient Ischemic Attack (TIA)

Kwang-hyub C. Han

Hana Park, 
Songnam, KR 
Experienced in Transient Ischemic Attack (TIA)
Hana Park, 
Songnam, KR 
OverviewLocationsClinical Research

Overview

Kwang-hyub Han practices in Songnam, Republic of Korea. Mr. Han is rated as an Experienced expert by MediFind in the treatment of Transient Ischemic Attack (TIA). His top areas of expertise are Hepatitis B, Hepatitis, Liver Cancer, Hepatectomy, and Liver Transplant.

His clinical research consists of co-authoring 447 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Transient Ischemic Attack (TIA).

Gender
Male

Locations

Hana Park, Songnam, 463712, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drugs: Besifovir, Tenofovir
Study Phase: Phase 3
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Enrollment Status: Completed
Publish Date: December 05, 2022
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
Enrollment Status: Unknown
Publish Date: January 27, 2020
Intervention Type: Drug
Study Drugs: Besifovir, Tenofovir
Study Phase: Phase 3
View 2 Less Clinical Trials

447 Total Publications

Properties of Cosmic Lithium Isotopes Measured by the Alpha Magnetic Spectrometer.
Properties of Cosmic Lithium Isotopes Measured by the Alpha Magnetic Spectrometer.
Journal: Physical review letters
Published: December 19, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Han's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile